BR9808422A - Composto, composição farmacêutica, processos para induzir paralisia neuromuscular em um mamìfero e para a preparação de um composto, e, uso de um composto - Google Patents

Composto, composição farmacêutica, processos para induzir paralisia neuromuscular em um mamìfero e para a preparação de um composto, e, uso de um composto

Info

Publication number
BR9808422A
BR9808422A BR9808422-4A BR9808422A BR9808422A BR 9808422 A BR9808422 A BR 9808422A BR 9808422 A BR9808422 A BR 9808422A BR 9808422 A BR9808422 A BR 9808422A
Authority
BR
Brazil
Prior art keywords
compound
processes
preparation
pharmaceutical composition
mammal
Prior art date
Application number
BR9808422-4A
Other languages
English (en)
Other versions
BR9808422B1 (pt
Inventor
Eric Cleveland Bigham
Eric Eugene Boros
Grady Evan Boswell
Robert Anthony Mook Jr.
Sanjay Shashikant Patel
Vicente Samano
John Joseph Savarese
Roy Archibald Swaringen
Original Assignee
Glaxo Group Ltd
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9706117.0A external-priority patent/GB9706117D0/en
Priority claimed from GBGB9724987.4A external-priority patent/GB9724987D0/en
Application filed by Glaxo Group Ltd, Cornell Res Foundation Inc filed Critical Glaxo Group Ltd
Publication of BR9808422A publication Critical patent/BR9808422A/pt
Publication of BR9808422B1 publication Critical patent/BR9808422B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSOS PARA INDUZIR PARALISIA NEUROMUSCULAR EM UM MAMìFERO E PARA A PREPARAçãO DE UM COMPOSTO, E, USO DE UM COMPOSTO". Os agentes bloqueadores neuromusculares de ação ultra curta da fórmula (I): que são utilizáveis como relaxantes do músculo do esqueleto durante os procedimentos de intubação de emergência, rotina cirúrgica e procedimentos pós operatórios são divulgados, em que X é halogênio; h é de 1 a 2 ; Y é hidrogênio ou metóxi; Z^ 1^e Z^ 2^ são metila; W^ 1^ e W^ 2^ são carbono; e A é um ânion farmaceuticamente aceitável.
BRPI9808422-4A 1997-03-25 1998-03-23 composto, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto. BR9808422B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9706117.0A GB9706117D0 (en) 1997-03-25 1997-03-25 Ultra-short acting neuromuscular blockers
GBGB9724987.4A GB9724987D0 (en) 1997-11-27 1997-11-27 Ultra-short acting neuromuscular blockers
PCT/EP1998/001651 WO1998042674A1 (en) 1997-03-25 1998-03-23 Substituted isoquinolines as ultra short acting neuromuscular blockers

Publications (2)

Publication Number Publication Date
BR9808422A true BR9808422A (pt) 2000-05-23
BR9808422B1 BR9808422B1 (pt) 2010-08-24

Family

ID=26311255

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9808422-4A BR9808422B1 (pt) 1997-03-25 1998-03-23 composto, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.

Country Status (37)

Country Link
US (2) US6187789B1 (pt)
EP (4) EP0975599B1 (pt)
JP (3) JP4112016B2 (pt)
KR (2) KR100578443B1 (pt)
CN (1) CN1203061C (pt)
AP (1) AP1797A (pt)
AR (1) AR012156A1 (pt)
AT (3) ATE254107T1 (pt)
AU (2) AU6730598A (pt)
BR (1) BR9808422B1 (pt)
CA (1) CA2284802C (pt)
CO (1) CO4940499A1 (pt)
CZ (1) CZ293786B6 (pt)
DE (3) DE69830157T2 (pt)
DK (2) DK0971898T3 (pt)
EA (1) EA002224B1 (pt)
EE (1) EE04113B1 (pt)
ES (2) ES2242275T3 (pt)
HK (1) HK1023342A1 (pt)
HR (1) HRP980157B1 (pt)
HU (1) HU228230B1 (pt)
ID (1) ID22901A (pt)
IL (1) IL131918A (pt)
IS (2) IS2346B (pt)
MA (1) MA26476A1 (pt)
MY (1) MY121316A (pt)
NO (1) NO314726B1 (pt)
NZ (1) NZ337797A (pt)
PE (1) PE68399A1 (pt)
PL (1) PL190860B1 (pt)
PT (2) PT975599E (pt)
RS (1) RS49869B (pt)
SI (1) SI0975599T1 (pt)
TR (1) TR199902330T2 (pt)
TW (1) TW505635B (pt)
UY (1) UY24933A1 (pt)
WO (2) WO1998042675A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49869B (sr) * 1997-03-25 2008-08-07 Avera Pharmaceuticals Inc., Supstituisani izohinolini kao neuromuskularni blokatori ultrakratkog delovanja
US6911455B2 (en) 1999-12-22 2005-06-28 Smithkline Beecham Corporation Methods for preparing pharmaceutical formulations
US6844904B2 (en) * 2002-12-07 2005-01-18 Cubic Corporation Fast PDLC device
US20050192243A1 (en) * 2003-10-28 2005-09-01 Savarese John J. Neuromuscular blocking agents and antagonists thereof
WO2008070121A1 (en) * 2006-12-06 2008-06-12 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
BRPI0808272A2 (pt) * 2007-03-08 2014-07-08 Chemagis Ltd "método para cromatograficamente separar o isômero 1r-cis, 1´r-cis de uma mistura de isômeros de (1r-1'r) - atracúrio, besilato de cisatracúrio e isômero 1r-cis, 1'r-cis do besilato de cisatracúrio"
CA2681060A1 (en) * 2007-03-26 2008-10-02 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
EP2155684B1 (en) * 2007-05-01 2014-04-09 Chemagis Ltd. Process for producing cisatracurium compounds and associated intermediates
WO2008132746A1 (en) * 2007-05-01 2008-11-06 Chemagis Ltd. Novel isoquinolinium compounds useful in the preparation of cisatracurium and associated intermediates
EP2132181A1 (en) * 2007-06-18 2009-12-16 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
BRPI0812625A2 (pt) * 2007-07-09 2019-02-19 Chemagis Ltd processo para preparar um sal de cis-atracúrio
EP2197848A1 (en) * 2007-10-29 2010-06-23 Chemagis Ltd. Novel r,r'-atracurium salts
AU2009241211A1 (en) * 2008-05-01 2009-11-05 Chemagis Ltd. Cisatracurium derivatives, preparation and uses thereof
WO2010107488A1 (en) * 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
WO2011022491A1 (en) 2009-08-19 2011-02-24 Cornell University Cysteine for physiological injection
US9156826B2 (en) * 2012-06-29 2015-10-13 Cornell University Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration
CN103373959A (zh) * 2013-06-14 2013-10-30 安徽省先锋制药有限公司 顺式苄基异喹啉类化合物的制备方法及其用途
WO2014210369A2 (en) * 2013-06-28 2014-12-31 Cornell University Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents
CN108375644B (zh) * 2016-12-07 2021-11-30 四川科瑞德制药股份有限公司 一种神经肌肉阻滞剂中间体的分析方法
CN108938573B (zh) * 2017-05-26 2021-08-10 四川科瑞德制药股份有限公司 一种神经肌肉阻滞剂组合物及其制备方法和用途
CN110776481B (zh) * 2018-07-24 2023-06-16 四川大学华西医院 一类双阳离子化合物及其制备方法和用途
CN109776486A (zh) * 2019-02-26 2019-05-21 武汉松石科技股份有限公司 一种硫酸亚丙酯的制备方法
CN111662230A (zh) * 2019-03-06 2020-09-15 四川道珍科技有限公司 一类苄基异喹啉化合物、制备方法和用途
CN110117297A (zh) * 2019-04-10 2019-08-13 珠海市赛纬电子材料股份有限公司 一种2-磷酸盐基硫酸丙烯酯的制备方法
TW202128628A (zh) * 2019-12-11 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 神經肌肉阻滯劑及其製備方法
CN111471013B (zh) * 2020-05-26 2021-04-30 朗天药业(湖北)有限公司 一种米库氯铵及其注射液的制备方法
CN111909089B (zh) * 2020-08-14 2023-04-14 广东嘉博制药有限公司 一种米库氯铵对照品的制备方法
CN114057642B (zh) * 2021-12-10 2023-03-28 广东嘉博制药有限公司 一种米库氯铵中间体的合成方法
CN115073373A (zh) * 2022-07-08 2022-09-20 广东嘉博制药有限公司 一种不对称合成（r）-5’-甲氧基劳丹素的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004031A (en) * 1958-07-03 1961-10-10 Allen & Hauburys Ltd Diquaternary salts of papaverino esters
AU506657B2 (en) * 1975-12-10 1980-01-17 Wellcome Foundation Limited, The Isoquinoline derivatives
SU862820A3 (ru) * 1977-08-01 1981-09-07 Дзе Массачусетс Дженерал Хоспитал (Фирма) Способ получени производных изохинолини
US4701460A (en) * 1980-12-17 1987-10-20 Burroughs Wellcome Co. Long duration neuromuscular blocking agents
JPS5899465A (ja) * 1981-11-23 1983-06-13 ザ・ウエルカム・フアウンデ−シヨン・リミテツド イソキノリン誘導体
GB8418303D0 (en) * 1984-07-18 1984-08-22 Wellcome Found Compounds
BG41897A1 (en) * 1985-07-19 1987-09-15 Ivanov Dichlormethylate of n, n'- 4, 10- dioxa- 3, 11- bis- tetrahydropapaverine and method for its preparation
GB9015473D0 (en) * 1990-07-13 1990-08-29 Wellcome Found Neuromuscular blocking agents
JPH04112016A (ja) * 1990-09-03 1992-04-14 Fuji Electric Co Ltd トランスファ成形金型用プランジャ及びトランスファ成形装置
US5240939A (en) * 1991-10-31 1993-08-31 Anaquest, Inc. Nitrogen bridge tetrahydroisoquinolines
RS49869B (sr) * 1997-03-25 2008-08-07 Avera Pharmaceuticals Inc., Supstituisani izohinolini kao neuromuskularni blokatori ultrakratkog delovanja

Also Published As

Publication number Publication date
DE69840816D1 (de) 2009-06-18
JP4112016B2 (ja) 2008-07-02
NO994680L (no) 1999-11-24
CN1203061C (zh) 2005-05-25
NO314726B1 (no) 2003-05-12
EP0975599A1 (en) 2000-02-02
AP1797A (en) 2007-11-15
PT971898E (pt) 2005-07-29
HU228230B1 (en) 2013-02-28
TR199902330T2 (xx) 2000-02-21
DK0971898T3 (da) 2005-09-05
EP1380573B1 (en) 2009-05-06
HUP0001556A3 (en) 2002-01-28
ID22901A (id) 1999-12-16
BR9808422B1 (pt) 2010-08-24
DE69819703D1 (de) 2003-12-18
EA199900756A1 (ru) 2000-08-28
JP2008019272A (ja) 2008-01-31
NO994680D0 (no) 1999-09-24
IL131918A0 (en) 2001-03-19
SI0975599T1 (en) 2004-04-30
ATE430734T1 (de) 2009-05-15
YU48399A (sh) 2002-06-19
EP1526130A1 (en) 2005-04-27
EP1380573A3 (en) 2004-01-21
JP4112015B2 (ja) 2008-07-02
CA2284802A1 (en) 1998-10-01
ATE295351T1 (de) 2005-05-15
IS2346B (is) 2008-03-15
RS49869B (sr) 2008-08-07
AU745382B2 (en) 2002-03-21
ES2242275T3 (es) 2005-11-01
UY24933A1 (es) 2000-12-29
EA002224B1 (ru) 2002-02-28
AU6730598A (en) 1998-10-20
CA2284802C (en) 2009-06-16
KR20050103984A (ko) 2005-11-01
EP1380573A2 (en) 2004-01-14
ES2210757T3 (es) 2004-07-01
MA26476A1 (fr) 2004-12-20
ATE254107T1 (de) 2003-11-15
MY121316A (en) 2006-01-28
HUP0001556A2 (hu) 2001-04-28
DE69830157D1 (de) 2005-06-16
KR100578443B1 (ko) 2006-05-11
IS8717A (is) 2008-03-03
NZ337797A (en) 2001-03-30
DK0975599T3 (da) 2004-03-15
IL131918A (en) 2005-09-25
CZ340499A3 (cs) 2000-04-12
EP0971898B1 (en) 2005-05-11
WO1998042674A1 (en) 1998-10-01
TW505635B (en) 2002-10-11
PE68399A1 (es) 1999-07-23
DE69830157T2 (de) 2006-05-11
PL335885A1 (en) 2000-05-22
JP2002517168A (ja) 2002-06-11
AR012156A1 (es) 2000-09-27
KR20010005621A (ko) 2001-01-15
HRP980157A2 (en) 1999-02-28
EE9900424A (et) 2000-04-17
US6187789B1 (en) 2001-02-13
HRP980157B1 (en) 2004-10-31
KR100554601B1 (ko) 2006-03-03
IS5185A (is) 1999-09-17
JP2002503220A (ja) 2002-01-29
US6177445B1 (en) 2001-01-23
EE04113B1 (et) 2003-08-15
PL190860B1 (pl) 2006-02-28
CN1257483A (zh) 2000-06-21
CO4940499A1 (es) 2000-07-24
WO1998042675A1 (en) 1998-10-01
HK1023342A1 (en) 2000-09-08
PT975599E (pt) 2004-03-31
CZ293786B6 (cs) 2004-07-14
EP0971898A1 (en) 2000-01-19
EP0975599B1 (en) 2003-11-12
AP9901658A0 (en) 1999-09-30
AU7521098A (en) 1998-10-20
DE69819703T2 (de) 2004-09-30

Similar Documents

Publication Publication Date Title
BR9808422A (pt) Composto, composição farmacêutica, processos para induzir paralisia neuromuscular em um mamìfero e para a preparação de um composto, e, uso de um composto
BR9813973A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição.
BR0009696A (pt) Compostos esteróides ou seus sais, uso dos mesmos, e, formulações farmacêuticas
BR0206985A (pt) Anticorpos modificados e métodos de uso
TR199901411T2 (xx) Analjezik etkili yeni bile�imler.
MX9701292A (es) Compuestos espiro-azabiciclicos utiles en la terapia.
BR9809481A (pt) Composto, processo para sua preparação, uso do mesmo, composição farmacêutica, e, processos para sua preparação, para efetuar a imunossupressão e para tratar ou reduzir o risco de uma doença obstrutiva reversìvel das vias aéreas em um paciente
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR9813976A (pt) Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um paciente, e, para a preparação de um composto.
BR9911362A (pt) Artigos absorventes com uma banda de estiramento e métodos de fazer os mesmos
IL145602A0 (en) Pharmaceutical compounds
BR9809994A (pt) Composição farmacêutica para uso no tratamento da sìndrome do intestino irritável, diarréia, constipação, dor abdominal e/ou inchamento ou distensão abdominal em um mamìfero, uso de um ou mais compostos de vanilóide, seus sais, análogos e derivados famaceuticamente aceitáveis, e, processos para tratamento da sìndrome do intestino irritável, diarréia, constipação, dor abdominal e/ou inchamento ou distensão abdominal de um mamìfero e para a fabricação de uma composição
ATE6507T1 (de) Piperidinderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ZA796651B (en) New amino-pyrimidine-carbanilides, processes for their preparation, medicaments containing these compounds and their use and also diamino-pyrimidinecarbanilides and processes for their preparation
ATE330959T1 (de) Allosterische adenosin-rezeptor-modulatore
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
BR9910908A (pt) Indenopirrolocarbazóis ligados em ponte
YU19399A (sh) Lokalni anestetik za spoljnu upotrebu
ES2054902T3 (es) Para-aminofenoles 3-sustituidos, su procedimiento de preparacion, su empleo en la tincion de fibras queratinicas y compuestos intermedios utilizados en el procedimiento de preparacion.
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
MX9204637A (es) Nuevos derivados de pirazina y procedimiento para su preparacion.
BR9811298A (pt) Uso de um composto de vanádio fisiologicamente aceitável
BR9808042A (pt) Composto, composição farmacêutica, e, processo para preparação de compostos.
ES533261A0 (es) Procedimiento para la preparacion de 1-alquil-androsta-1,4-dien-3,17-dionas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CORNELL RESEARCH FOUNDATION, INC. (US) , AVERA PHA

Free format text: TRANSFERIDO DE: GLAXO GROUP LIMITED

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/08/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: CORNELL RESEARCH FOUNDATION, INC. (US) , AVERA PHA

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020110116524/RJ DE 11/11/2011.

B25A Requested transfer of rights approved

Owner name: CORNELL RESEARCH FOUNDATION, INC. (US) , MARUISHI

Free format text: TRANSFERIDO DE: AVERA PHARMACEUTICALS, INC.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2307 DE 24-03-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.